久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris

firstwordpharmaMarch 15, 2019

Tag: Roche , mabthera , pemphigus vulgaris

Roche announced Friday that regulators in Europe approved MabThera (rituximab) for the treatment of adults with moderate-to-severe pemphigus vulgaris (PV). The company noted that the drug "is the first biologic therapy approved by the European Commission for PV and the first major advancement in the treatment of the disease in more than 60 years."

The FDA approved MabThera in June last year for the treatment of patients with PV.

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction

Next:Bristol-Myers Squibb denies defensive strategy

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service